Q3 2024 EPS Estimates for Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Cut by HC Wainwright

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at HC Wainwright reduced their Q3 2024 EPS estimates for shares of Dianthus Therapeutics in a research note issued to investors on Monday, August 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.53) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.33) EPS, Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($4.49) EPS, FY2027 earnings at ($4.88) EPS and FY2028 earnings at ($3.72) EPS.

Several other brokerages have also recently commented on DNTH. Lifesci Capital upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Tuesday, June 11th. Baird R W upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an "outperform" rating and a $58.00 target price for the company. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They set an "overweight" rating on the stock. Finally, Wedbush decreased their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $44.71.

Dianthus Therapeutics Stock Performance

Shares of DNTH traded up $2.03 during mid-day trading on Wednesday, reaching $28.50. 126,486 shares of the company were exchanged, compared to its average volume of 193,266. The business has a 50 day simple moving average of $26.65 and a two-hundred day simple moving average of $25.24. The stock has a market capitalization of $836.45 million, a PE ratio of -4.89 and a beta of 1.89. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Tower Research Capital LLC TRC acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $25,000. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics during the 2nd quarter valued at $112,000. American Century Companies Inc. increased its stake in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after purchasing an additional 8,473 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics during the second quarter worth $265,000. Finally, Point72 DIFC Ltd bought a new position in shares of Dianthus Therapeutics in the second quarter valued at $334,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.